GlassScriptPhysician profile
Scott A Fulton
NPI 1922024181
$5,382.41
in general payments reported to CMS, 2019-2025
24 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $461 · 2021: $429 · 2022: $665 · 2023: $1,078 · 2024: $524 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,153.54 | 2019-2025 | Veklury, Biktarvy |
| Janssen Biotech, INC. | $956.01 | 2019-2023 | Symtuza, Stelara |
| Janssen Products, LP | $639.56 | 2019-2023 | Symtuza |
| Viiv Healthcare Company | $592.52 | 2019-2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $463.56 | 2019-2025 | Zerbaxa, Dificid, Prevymis |
| Melinta Therapeutics, LLC | $275.07 | 2019-2023 | Orbactiv, Kimyrsa, Vabomere |
| Insmed, INC. | $237.90 | 2019-2025 | Arikayce |
| Shionogi INC | $206.87 | 2023-2025 | Fetroja |
| Boston Scientific Corporation | $171.64 | 2019 | |
| Napo Pharmaceuticals INC | $136.73 | 2020-2024 | Mytesi |
| Astellas Pharma US INC | $90.91 | 2022-2025 | Cresemba |
| Abbvie INC. | $88.15 | 2023-2025 | |
| Tetraphase Pharmaceuticals, INC. | $72.02 | 2019-2020 | |
| Allergan, INC. | $56.46 | 2019-2020 | |
| Theratechnologies INC. | $48.02 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.71 | 2023-2024 | Entyvio |
| Amryt Pharma Holdings LTD | $24.66 | 2022 | |
| La Jolla Pharmaceutical Company | $23.10 | 2025 | Zevtera |
| Braintree Laboratories, INC. | $21.69 | 2022 | |
| Aimmune Therapeutics, INC. | $19.02 | 2023 | |
| Angiodynamics, INC. | $18.30 | 2020 | |
| Nabriva Therapeutics, Plc | $17.41 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.89 | 2021 | |
| Novo Nordisk INC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Fulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.